Search research articles
Contact Us
Filters
Showing results (111-120 of 183) with videos related to
Page
of 19
Sort By:
Journal of the National Cancer Institute
|
November 9, 2017
Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma
Eric A Hungate, Mark A Applebaum, Andrew D Skol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 27, 2014
Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project
Kieuhoa T Vo, Katherine K Matthay, John Neuhaus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 5, 2011
Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age
Denah R Taggart, Wendy B London, Mary Lou Schmidt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 19, 2008
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors
Elizabeth Fox, John M Maris, Brigitte C Widemann, et al.
Pediatric Blood & Cancer
|
September 11, 2018
Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma
Elizabeth A Sokol, Roger Engelmann, Wenjun Kang, et al.
Pediatric Blood & Cancer
|
November 28, 2018
The challenge of defining "ultra-high-risk" neuroblastoma
Daniel A Morgenstern, Rochelle Bagatell, Susan L Cohn, et al.
The American Journal of Surgical Pathology
|
March 19, 2021
Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group
Asuka Kawano, Florette K Hazard, Bill Chiu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 27, 2013
Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group
Gregory A Yanik, Marguerite T Parisi, Barry L Shulkin, et al.
Clinical and Translational Science
|
June 11, 2026
A Bayesian-Based Integrative Bioinformatics Analysis Nominates Oncogenic Drivers in Neuroblastoma
Lin Xu, Arhanti Sadanand, Evan W Neczypor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2020
Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project
Elizabeth Sokol, Ami V Desai, Mark A Applebaum, et al.
Page
of 19
Search research articles
Search
Showing results (111-120 of 183) with videos related to
Sort By:
Page
of 19
Journal of the National Cancer Institute
|
November 9, 2017
Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma
Eric A Hungate, Mark A Applebaum, Andrew D Skol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 27, 2014
Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project
Kieuhoa T Vo, Katherine K Matthay, John Neuhaus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 5, 2011
Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age
Denah R Taggart, Wendy B London, Mary Lou Schmidt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 19, 2008
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors
Elizabeth Fox, John M Maris, Brigitte C Widemann, et al.
Pediatric Blood & Cancer
|
September 11, 2018
Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma
Elizabeth A Sokol, Roger Engelmann, Wenjun Kang, et al.
Pediatric Blood & Cancer
|
November 28, 2018
The challenge of defining "ultra-high-risk" neuroblastoma
Daniel A Morgenstern, Rochelle Bagatell, Susan L Cohn, et al.
The American Journal of Surgical Pathology
|
March 19, 2021
Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group
Asuka Kawano, Florette K Hazard, Bill Chiu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 27, 2013
Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group
Gregory A Yanik, Marguerite T Parisi, Barry L Shulkin, et al.
Clinical and Translational Science
|
June 11, 2026
A Bayesian-Based Integrative Bioinformatics Analysis Nominates Oncogenic Drivers in Neuroblastoma
Lin Xu, Arhanti Sadanand, Evan W Neczypor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2020
Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project
Elizabeth Sokol, Ami V Desai, Mark A Applebaum, et al.
Page
of 19